Search results
Results from the WOW.Com Content Network
ntp.niehs.nih.gov The National Toxicology Program ( NTP ) is an inter-agency program run by the United States Department of Health and Human Services to coordinate, evaluate, and report on toxicology within public agencies.
The National Institute of Environmental Health Sciences (NIEHS) conducts research into the effects of the environment on human disease, as one of the 27 institutes and centers of the National Institutes of Health (NIH). It is located in the Research Triangle Park in North Carolina, and is the only primary division of the NIH located outside of ...
NIDA has also conducted research into diseases associated with drug use, such as AIDS and Hepatitis. NIDA views drug treatment as a means of modifying risky behavior such as unprotected sex and sharing needles. NIDA has also funded studies dealing with harm reduction. A NIDA-supported study on pregnant drug users noted, "professionals in ...
coordinates NIH activities regarding the application of research to disease prevention, nutrition and medical practice. The ODP is housed within the Division of Program Coordination, Planning, and Strategic Initiatives , Office of the Director (OD), National Institutes of Health (NIH). [15] prevention.nih.gov
Research has shown, when drug use begins at an early age, there is a greater possibility for addiction to occur. [14] Three exacerbating factors that can influence substance use to become substance use are social approval, lack of perceived risks , and availability of drugs in the community .
The NIH Office of Science Policy works on a wide range of issues including biosafety, [2] biosecurity, [3] genetic testing, genomic data sharing, [4] human subjects protections, [5] the organization and management of the NIH, and the outputs and value of NIH-funded research. This is accomplished through a wide range of analyses and reports ...
Pharmacovigilance (PV, or PhV), also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products.
Between 1998 and 2007, 33 serious adverse drug or device reactions have been reported by RADAR investigators. The toxicities involved multiple biological system and included thrombotic thrombocytopenic purpura (TTP) (ticlopidine and clopidogrel), thromboembolism (thalidomide and lenalidomide), liver failure (gemtuzumab and nevirapine), hypersensitivity (drug eluting coronary arterial stents ...